These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9385482)

  • 1. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
    Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
    Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
    Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
    Lipsky BA; Miller B; Schwartz R; Henry DC; Nolan T; McCabe A; Magner DJ; Talbot GH
    Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
    Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
    Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA; Dorr MB; Magner DJ; Talbot GH
    Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
    Gotfried MH; Ellison WT
    Am J Med; 1992 Apr; 92(4A):108S-113S. PubMed ID: 1316059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
    Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
    Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
    Portier H; May T; Proust A
    J Antimicrob Chemother; 1996 May; 37 Suppl A():83-91. PubMed ID: 8737128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.
    Drehobl M; Bianchi P; Keyserling CH; Tack KJ; Griffin TJ
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1579-83. PubMed ID: 9210689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
    Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
    Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B; Dutchman DA; Pettit R; Maroli A
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
    DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
    Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
    Lode H; Garau J; Grassi C; Hosie J; Huchon G; Legakis N; Segev S; Wijnands G
    Eur Respir J; 1995 Dec; 8(12):1999-2007. PubMed ID: 8666093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia].
    Jiang XT; Du YP; Deng LP
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1876-8. PubMed ID: 15631797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
    Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
    Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
    Lipsky BA; Unowsky J; Zhang H; Townsend L; Talbot GH
    Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
    Henry D; Ellison W; Sullivan J; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2262-6. PubMed ID: 9736546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.